Clinical Scorecard: FGF8 Enhances Host Anti-Infective Immunity and Offers Protection Against Polymicrobial Sepsis

At a Glance

Key Highlights

• FGF8 protein levels are elevated in septic mice and human patients with sepsis compared to controls.
• Blockade of FGF8 increases mortality, bacterial burden, and tissue injury in septic mice.
• Therapeutic recombinant FGF8 administration improves bacterial clearance and survival in sepsis via FGFR1-dependent ERK1/2 pathway activation.

Guideline-Based Recommendations

Diagnosis

• Measure serum FGF8 levels as an adjunct biomarker for sepsis diagnosis in adult and pediatric ICU patients.

Management

• Consider therapeutic administration of recombinant FGF8 to enhance host immune defense and improve survival in polymicrobial sepsis.
• Avoid FGF8 blockade during sepsis as it worsens outcomes.

Monitoring & Follow-up

• Monitor serum FGF8 concentrations to assess immune response status during sepsis.

Risks

• Potential risks of immunosuppression and increased bacterial burden if FGF8 activity is inhibited.

Patient & Prescribing Data

Adult and pediatric patients with sepsis meeting Sepsis-3 criteria and Phoenix sepsis score ≥ 2

Recombinant FGF8 improves bacterial clearance and reduces mortality in sepsis models; clinical serum levels correlate with disease presence.

Clinical Best Practices

• Use FGF8 serum level measurement as a supplementary diagnostic tool in sepsis evaluation.
• Employ recombinant FGF8 therapy to enhance macrophage-mediated bacterial clearance via FGFR1 and ERK1/2 signaling.
• Avoid immunosuppressive treatments that may interfere with FGF8 signaling during sepsis management.
• Apply CLP-induced sepsis animal models to further investigate FGF8-targeted therapies.

References

• Sepsis-3 Clinical Criteria
• FGF8 Role in Immune Regulation
• Cecal Ligation and Puncture (CLP) Model